Domain Therapeutics, a developer of immuno-oncology drug candidates targeting G protein-coupled receptors (GPCRs), has promoted Stephan Schann to chief scientific officer from vice president of research. Dr Schann has worked at Domain since its inception in 2008 and in his new role will oversee the development of Domain’s proprietary pipeline and its R&D centre in Strasbourg, France.
Domain announced the appointment on 27 February 2024.
Copyright 2024 Evernow Publishing Ltd